Evidence map›Paper›PMID 22363793›Full record

ArticlePloS one2012

Toward low-cost affinity reagents: lyophilized yeast-scFv probes specific for pathogen antigens.

Sean A Gray, Kris M Weigel, Ibne K M Ali, Annie A Lakey, Jeremy Capalungan, Gonzalo J Domingo, Gerard A Cangelosi

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Sean A GraySeattle Biomedical Research Institute, Seattle, Washington, United States of America.
Kris M Weigel
Ibne K M Ali
Annie A Lakey
Jeremy Capalungan
Gonzalo J Domingo
Gerard A Cangelosi
Center for Infectious Disease Research · USProgram for Appropriate Technology in Health · USUniversity of Virginia Health System · US

Funding

Accelerated molecular probe pipelineU01AI082186 · NIAID · UNIVERSITY OF WASHINGTON · PI CANGELOSI, GERARD A · 2009 to 2013
$4.7M
NIAID NIH HHS R21 AI0744571NIAID NIH HHS U01 AI082186NIAID NIH HHS U01AI082186
6 · The paper itself

Abstract

The generation of affinity reagents, usually monoclonal antibodies, remains a critical bottleneck in biomedical research and diagnostic test development. Recombinant antibody-like proteins such as scFv have yet to replace traditional monoclonal antibodies in antigen detection applications, in large part because of poor performance of scFv in solution. To address this limitation, we have developed assays that use whole yeast cells expressing scFv on their surfaces (yeast-scFv) in place of soluble purified scFv or traditional monoclonal antibodies. In this study, a nonimmune library of human scFv displayed on the surfaces of yeast cells was screened for clones that bind to recombinant cyst proteins of Entamoeba histolytica, an enteric pathogen of humans. Selected yeast-scFv clones were stabilized by lyophilization and used in detection assay formats in which the yeast-scFv served as solid support-bound monoclonal antibodies. Specific binding of antigen to the yeast-scFv was detected by staining with rabbit polyclonal antibodies. In flow cytometry-based assays, lyophilized yeast-scFv reagents retained full binding activity and specificity for their cognate antigens after 4 weeks of storage at room temperature in the absence of desiccants or stabilizers. Because flow cytometry is not available to all potential assay users, an immunofluorescence assay was also developed that detects antigen with similar sensitivity and specificity. Antigen-specific whole-cell yeast-scFv reagents can be selected from nonimmune libraries in 2-3 weeks, produced in vast quantities, and packaged in lyophilized form for extended shelf life. Lyophilized yeast-scFv show promise as low cost, renewable alternatives to monoclonal antibodies for diagnosis and research.

Indexed as

Antibodies, MonoclonalAntigens, ProtozoanCosts and Cost AnalysisEntamoeba histolyticaFluorescent Antibody TechniqueFreeze DryingHumansIndicators and ReagentsLimit of DetectionMicroscopy, FluorescenceMolecular ProbesProtozoan ProteinsSaccharomyces cerevisiaeSingle-Chain AntibodiesTime FactorsAntibodies, MonoclonalAntigens, ProtozoanIndicators and ReagentsMolecular ProbesProtozoan ProteinsSingle-Chain Antibodies

Identifiers

PMID22363793
PMCPMC3282784
OpenAlexW1994320069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.